Bolli N, D'Agostino M, Bagratuni T, Boccadoro M, Cavo M, Driessen C, Einsele H, Engelhardt M, Gay F, Gutiérrez NC, Hájek R, Holien T, João C, Kaiser M, Kortüm KM, Leypoldt L, Moreau P, Musto P, Ocio EM, Raab MS, Rasche L, Schjesvold F, Sevcikova T, Terpos E, Touzeau Cet al.(2025) European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma Hemasphere, 9(10), e70216 DOI 10.1002/hem3.70216, PubMed 41089883
Thorsteinsdóttir S, Lemonakis K, Slørdahl TS, Rögnvaldsson S, Richardson AK, Hermansen E, Thorsen J, Schjesvold F, Moore KLF, Szabo AG, Andersen MK, Waage A, Blimark CH, Vangsted A, Nordic Myeloma Study Group(2025) Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group Br J Haematol, 207(4), 1638-1642 DOI 10.1111/bjh.70030, PubMed 41070698
Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted AJ, Vieyra D, Attar RM, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro Met al.(2025) Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone Blood(in press) DOI 10.1182/blood.2025030113, PubMed 41060326
